It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Small nucleotide variants in non-coding regions of the genome can alter transcriptional regulation, leading to changes in gene expression which can activate oncogenic gene regulatory networks. Melanoma is heavily burdened by non-coding variants, representing over 99% of total genetic variation, including the well-characterized TERT promoter mutation. However, the compendium of regulatory non-coding variants is likely still functionally under-characterized. We developed a pipeline to identify hotspots, i.e. recurrently mutated regions, in melanoma containing putatively functional non-coding somatic variants that are located within predicted melanoma-specific regulatory regions. We identified hundreds of statistically significant hotspots, including the hotspot containing the TERT promoter variants, and focused on a hotspot in the promoter of CDC20. We found that variants in the promoter of CDC20, which putatively disrupt an ETS motif, lead to lower transcriptional activity in reporter assays. Using CRISPR/Cas9, we generated an indel in the CDC20 promoter in human A375 melanoma cell lines and observed decreased expression of CDC20, changes in migration capabilities, increased growth of xenografts, and an altered transcriptional state previously associated with a more proliferative and less migratory state. Overall, our analysis prioritized several recurrent functional non-coding variants that, through downregulation of CDC20, led to perturbation of key melanoma phenotypes.
A non-coding variant upstream of the CDC20 promoter leads to down-regulation of CDC20 expression and up-regulation of a more proliferative and melanocytic transcriptional program that may aid in accelerating tumor growth.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Washington University School of Medicine, Division of Medical Oncology, Department of Medicine and Department of Developmental Biology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
2 Washington University School of Medicine, Department of Surgery, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
3 Washington University School of Medicine, Departments of Medicine (Oncology) and Cell Biology and Physiology and the ICCE Institute, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
4 Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Departments of Medicine (Oncology) and Cell Biology and Physiology and the ICCE Institute, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
5 Washington University School of Medicine, Division of Medical Oncology, Department of Medicine and Department of Developmental Biology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)